DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
January 19 2021 - 4:30PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in
precision dermatology enabled by a non-invasive skin genomics
platform, announced today its presentation at the 2021 Dermatology
Summit virtual conference (the “Dermatology Summit”) on Jan. 8,
2021. The Dermatology Summit uniquely brings together members of
the financial community and business leaders from established and
emerging companies in the dermatology space to help foster
investment and partnerships in the next generation of dermatology
companies and products.
DermTech Chief Scientific Officer, Michael Howell, Ph.D.,
participated in the Dermatology Summit Precision Medicine Showcase,
with a presentation titled, “Smart Sticker Enabled Precision
Dermatology.” Howell provided an overview of DermTech’s melanoma
test, the Pigmented Lesion Assay (“PLA”) and the company’s novel
and proprietary non-invasive smart sticker platform and their use
for the early detection of melanoma. Additionally, Howell presented
the smart sticker as an improved approach for precision and
personalized dermatology by non-invasively evaluating the
heterogeneity of large populations and stratifying patients based
on skin gene expression and protein profiles, identifying
biomarkers of specific diseases and disease subsets, and collecting
inflammatory signatures prior to and following treatments in order
to predict and track responses to therapeutic intervention. Howell
also highlighted the potential for DermTech’s smart sticker
platform to be used to sample lesions for tests that may be
developed in the future to address some of the more than 3,000
known skin diseases other than melanoma.
“The smart sticker exemplifies DermTech’s commitment to
precision and personalized dermatology,” commented Howell. “The
non-invasive nature of the smart sticker platform enables skin
sampling, even in these unprecedented times when office visits are
often being avoided, and allows for the integration of molecular
approaches such as genomics and proteomics to drive diagnostic,
predictive, prognostic and pharmacodynamic biomarker identification
and implementation in precision dermatology.”
The full presentation can be viewed here.
About DermTech
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform dermatology with our non-invasive skin genomics
platform, to democratize access to high quality dermatology care,
and to improve the lives of millions. DermTech provides genomic
analysis of skin samples collected non-invasively using an adhesive
patch rather than a scalpel. DermTech markets and develops products
that facilitate the early detection of skin cancers, and is
developing products that assess inflammatory diseases and customize
drug treatments. For additional information on DermTech, please
visit DermTech’s investor relations site at: www.DermTech.com.
Forward-looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, cost-effectiveness, commercialization and adoption of
DermTech’s products, including its smart sticker platform, and the
market opportunity therefor. These forward-looking statements
involve significant risks and uncertainties that could cause the
actual results to differ materially from the expected results. Most
of these factors are outside of the control of DermTech and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: (1) the outcome of any legal
proceedings that may be instituted against DermTech; (2) DermTech’s
ability to obtain additional funding to develop and market its
products; (3) the existence of favorable or unfavorable clinical
guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by Medicare and private payors; (5) the ability of
patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees; (7)
changes in applicable laws or regulations; (8) the market adoption
and demand for DermTech’s products and services together with the
possibility that DermTech may be adversely affected by other
economic, business, and/or competitive factors; and (9) other risks
and uncertainties included in (x) the “Risk Factors” section of the
most recent Quarterly Report on Form 10-Q filed by DermTech with
the Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005947/en/
DermTech Sarah Dion sdion@dermtech.com 858.450.4222
Crowe PR Sarah Gallagher sgallagher@crowepr.com 224.406.4709
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2023 to Apr 2024